Exendin-4 protects brain endothelial cell damage against hyperammonemic condition.

Area of Science:

• Neuroscience
• Pharmacology
• Gastroenterology

Background:

• Hepatic encephalopathy (HE) is a serious neuropsychiatric condition linked to high ammonia levels.
• Elevated ammonia damages the blood-brain barrier (BBB) and causes chronic neuroinflammation.
• Current treatments for HE focus on reducing ammonia, but BBB protection and anti-inflammatory strategies are needed.

Purpose of the Study:

• To investigate the therapeutic potential of exendin-4, a GLP-1 receptor agonist, in managing HE-related BBB dysfunction and neuroinflammation.
• To assess exendin-4's efficacy in preclinical HE models.

Main Methods:

• A bile duct ligation mouse model was used to induce HE, confirming hepatic impairment via liver enzyme levels.
• In vitro cell models mimicked hyperammonemia to assess BBB permeability, tight junction protein expression, and cytokine release.
• Exendin-4 treatment was applied to both in vivo and in vitro models.
• RNA sequencing was performed on endothelial cells treated with exendin-4.

Main Results:

• Hyperammonemia in HE models reduced tight junction proteins, increased oxidative stress, and induced apoptosis.
• In vitro, high ammonia increased endothelial cell permeability and decreased tight junction proteins (e.g., claudin-5).
• Exendin-4 treatment reversed these effects, preserving BBB integrity and reducing pro-inflammatory cytokine release.
• RNA sequencing revealed exendin-4 modulated gene expression in endothelial cells.

Conclusions:

• Exendin-4 demonstrates significant potential in mitigating hyperammonemia-induced BBB disruption and neuroinflammation.
• These findings support exendin-4 as a therapeutic agent for neuropathologies associated with HE.
• Further research into exendin-4's mechanisms and clinical application in HE is warranted.